Right to Try Act

This act governs patient access to investigational drugs, biological products, and devices, including individualized investigational treatments developed for a single patient. It authorizes eligible patients to obtain and use those treatments and builds a framework around that access — institutional review board involvement, annual reporting and rulemaking, restrictions on the purchase and sale of adult stem cells for certain investigational treatments, and provisions on insurance coverage of clinical trials. The remaining provisions allocate legal exposure: physicians and other health care providers may not be sanctioned for participating, certain conduct by government and state officials is prohibited, manufacturers are shielded from a private right of action, and a patient's heirs are not liable for outstanding debt related to the treatment.

Editorial summary generated from the text of this act. It is not part of the statute — read the sections below for the operative language.